MRK vs PFE
Merck & Co. Inc. and Pfizer Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | MRK | PFE |
|---|---|---|
| Revenue | $65.0B | $62.6B |
| Net income | $18.3B | $7.8B |
| Gross margin | 74.8% | 74.3% |
| Net margin | 28.1% | 12.5% |
| Return on equity | 36.9% | 8.9% |
| Diluted EPS | $7.28 | $1.36 |
| Dividend / share | $3.28 | $1.72 |
| Payout ratio | 44.8% | · |
| Free cash flow | $12.4B | $9.1B |
| Equity | $52.6B | $86.5B |
| Net debt / equity | 0.66× | 0.73× |
| Current ratio | 1.54× | 1.16× |
| Revenue CAGR 5y | 9.4% | 8.5% |
| Profit CAGR 5y | 20.9% | −3.2% |
MRK and PFE book revenue within 15% of each other, and keeps more of each dollar of revenue as profit (28.1% against 12.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | MRK | PFE |
|---|---|---|
| FY2025 | $65.0B | $62.6B |
| FY2024 | $64.2B | $63.6B |
| FY2023 | $60.1B | $59.6B |
| FY2022 | $59.3B | $101.2B |
| FY2021 | $48.7B | $81.3B |
| FY2020 | $41.5B | $41.7B |
| FY2019 | $39.1B | $40.9B |
| FY2018 | $42.3B | $40.8B |
| FY2017 | $40.1B | $52.5B |
| FY2016 | $39.8B | $52.8B |
Bottom line
| Fiscal year | MRK | PFE |
|---|---|---|
| FY2025 | $18.3B | $7.8B |
| FY2024 | $17.1B | $8.0B |
| FY2023 | $365.0M | $2.1B |
| FY2022 | $14.5B | $31.4B |
| FY2021 | $13.0B | $22.0B |
| FY2020 | $7.1B | $9.2B |
| FY2019 | $9.8B | $16.0B |
| FY2018 | $6.2B | $11.2B |
| FY2017 | $2.4B | $21.3B |
| FY2016 | $3.9B | $7.2B |
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$2,432,000,000 | MRK |
| FY2024 | +$541,000,000 | MRK |
| FY2023 | +$562,000,000 | MRK |
| FY2022 | −$41,892,000,000 | PFE |
| FY2021 | −$32,584,000,000 | PFE |
| FY2020 | −$133,000,000 | PFE |
| FY2019 | −$1,784,000,000 | PFE |
| FY2018 | +$1,469,000,000 | MRK |
| FY2017 | −$12,424,000,000 | PFE |
| FY2016 | −$13,017,000,000 | PFE |
| FY2015 | −$9,353,000,000 | PFE |
| FY2014 | −$7,368,000,000 | PFE |
| FY2013 | −$7,551,000,000 | PFE |
| FY2012 | −$7,390,000,000 | PFE |
| FY2011 | −$12,988,000,000 | PFE |
| FY2010 | −$19,178,000,000 | PFE |
| FY2009 | −$21,841,000,000 | PFE |
| FY2008 | −$24,446,000,000 | PFE |
| FY2007 | −$24,220,300,000 | PFE |
The higher-revenue side has changed between MRK and PFE over this period. The gap has narrowed since the earliest year compared.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +15.6 pp | MRK |
| FY2024 | +14.0 pp | MRK |
| FY2023 | −3.0 pp | PFE |
| FY2022 | −6.5 pp | PFE |
| FY2021 | −0.3 pp | PFE |
| FY2020 | −5.0 pp | PFE |
| FY2019 | −14.3 pp | PFE |
| FY2018 | −12.8 pp | PFE |
| FY2017 | −34.6 pp | PFE |
| FY2016 | −3.8 pp | PFE |
| FY2015 | −3.0 pp | PFE |
| FY2014 | +9.8 pp | MRK |
| FY2013 | −32.5 pp | PFE |
| FY2012 | −13.4 pp | PFE |
| FY2011 | −3.2 pp | PFE |
| FY2010 | −10.6 pp | PFE |
| FY2009 | +29.9 pp | MRK |
| FY2008 | +16.4 pp | MRK |
| FY2007 | −2.9 pp | PFE |
The higher net margin has changed hands between MRK and PFE over this period.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRK's net margin has been more volatile than PFE's over the 19 comparable fiscal years — 11.4 percentage points of standard deviation against 10.5.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between MRK and PFE over these 19 fiscal years — MRK led in 5 and PFE in 14.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRK's return on equity has been more volatile than PFE's over the 18 comparable fiscal years — 14.4 percentage points of standard deviation against 9.4.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between MRK and PFE over these 18 fiscal years — MRK led in 9 and PFE in 9.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.